Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumecitinib (PG-011) Nasal Spray in Seasonal Allergic Rhinitis
NCT07146126Phase 3Not yet recruiting
- Sponsor
- Prime Gene Therapeutics
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing PG-011 0.6% BID with Placebo BID (2 arms). Primary endpoint: Change from baseline in average retrospective Total Nasal Symptom Score at Day 14. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
pumecitinib
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT07146126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146126.